Mats Olof Strömqvist
Directeur Général chez Vakona AB
Profil
Mats Olof Strömqvist is currently the Chairman & Chief Executive Officer at Vakona AB since 2020.
He is also a Director at FOI - Totalförsvarets forskningsinstitut.
Previously, he was the Chief Executive Officer at Omnio Healer AB.
He was also the Chairman at Cantargia AB from 2011 to 2014.
Additionally, he worked as an Associate Director Molecular Biology at AstraZeneca AB and Pharmacia AB.
Postes actifs de Mats Olof Strömqvist
| Sociétés | Poste | Début |
|---|---|---|
| FOI - Totalförsvarets forskningsinstitut | Directeur/Membre du Conseil | - |
Vakona AB
 Vakona AB BiotechnologyHealth Technology Vakona is a Swedish company that is developing a new biological drug for the treatment of acne. The drug is based on a bacterial enzyme and has the potential to significantly reduce treatment time and side effects such as skin irritation. The company's research is based on over a decade of work by Dr. Oleg Alexeyev and aims to provide an alternative to the long-term inefficacy of current acne therapies that rely on antibiotics. The company was founded by Oleg Alexeyev and has CEOs Mats Olof Strömqvist and Gabriella Persson. | Directeur Général | 01/11/2020 |
Anciens postes connus de Mats Olof Strömqvist
| Sociétés | Poste | Fin |
|---|---|---|
| CANTARGIA AB | Président | 15/01/2014 |
Omnio Healer AB
 Omnio Healer AB Pharmaceuticals: MajorHealth Technology Omnio Healer AB is a company developing novel drug candidates based on a series of conceptual breakthroughs in inflammation research. This new, pro-inflammatory approach opens up completely new therapeutic strategies for wound healing and anti-infection. The company's lead drug candidate, aimed primarily at otological indications, has achieved promising preclinical results and will enter a clinical development program in late 2010. Since its foundation in 2006 Omnio Healer has assembled a management and development team. This includes scientists within the field, experienced product development professionals and active investors led by Karolinska Development AB, providing access to a network of biotechnology development resources. The company is based in Umeå, Sweden. | President | 19/01/2012 |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - |
| Pharmacia AB | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CANTARGIA AB | Health Technology |
| Entreprise privées | 5 |
|---|---|
Omnio Healer AB
Omnio Healer AB Pharmaceuticals: MajorHealth Technology Omnio Healer AB is a company developing novel drug candidates based on a series of conceptual breakthroughs in inflammation research. This new, pro-inflammatory approach opens up completely new therapeutic strategies for wound healing and anti-infection. The company's lead drug candidate, aimed primarily at otological indications, has achieved promising preclinical results and will enter a clinical development program in late 2010. Since its foundation in 2006 Omnio Healer has assembled a management and development team. This includes scientists within the field, experienced product development professionals and active investors led by Karolinska Development AB, providing access to a network of biotechnology development resources. The company is based in Umeå, Sweden. | Health Technology |
| Pharmacia AB | Health Technology |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
| FOI - Totalförsvarets forskningsinstitut | |
Vakona AB
Vakona AB BiotechnologyHealth Technology Vakona is a Swedish company that is developing a new biological drug for the treatment of acne. The drug is based on a bacterial enzyme and has the potential to significantly reduce treatment time and side effects such as skin irritation. The company's research is based on over a decade of work by Dr. Oleg Alexeyev and aims to provide an alternative to the long-term inefficacy of current acne therapies that rely on antibiotics. The company was founded by Oleg Alexeyev and has CEOs Mats Olof Strömqvist and Gabriella Persson. | Health Technology |